Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9471338 | 0.92 | DRD4 (0.62) | DRD4GRIN2BTAAR1 | |
| SCHEMBL2796995 | 0.83 | DRD4 (0.60) | DRD4GRIN2BSIGMAR1GRIN1TAAR1 | |
| SCHEMBL29238649 | 0.83 | DRD4 (0.61) | DRD4GRIN2B | |
| SCHEMBL4213070 | 0.83 | DRD4 (0.57) | DRD4GRIN2BSIGMAR1GRIN1FAAH | |
| SCHEMBL4202104 | 0.81 | GRIN2B (0.68) | DRD4GRIN2BSIGMAR1GRIN1SLC6A2 | |
| SCHEMBL27373891 | 0.79 | SLC18A3 (0.56) | — | |
| SCHEMBL29042881 | 0.78 | USP30 (0.55) | DRD4MCHR1 | |
| SCHEMBL29042870 | 0.78 | USP30 (0.55) | DRD4MCHR1 | |
| SCHEMBL5540465 | 0.78 | GRIN2B (0.58) | DRD4GRIN2BSIGMAR1GRIN1SLC6A2 | |
| SCHEMBL9249968 | 0.78 | POLB (0.56) | GRIN2BGRIN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | DRD4 2539/4885GRIN2B 1241/4885SIGMAR1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.